CD14

Chr 5q31.3

CD14 molecule

MANE:: ENST00000302014.11

OMIM: 158120 ↗NCBI: 929 ↗Ensembl ↗

Annotations refreshed 9 hours ago.

Predicted protein structure

AlphaFold predicted structure

CD14 · P08571

v62025-08-01

Predicted Aligned Error matrix for CD14 — diagonal shows residue index, colour shows pairwise prediction confidence (lower is better) — Predicted Aligned Error

Mean pLDDT

84.8/ 100

Confident

375 residues

Confidence breakdown

Very high(≥ 90)71%
Confident(70–90)11%
Low(50–70)4%
Very low(< 50)14%

Open interactive 3D viewer

AlphaFold (Jumper et al., 2021) · CC BY 4.0

Clinical relevance (Genomics England PanelApp)

Diagnostic Grade (Green)

COVID-19 research
Unknown

Disease associations (Open Targets)

dengue disease
0.39
inborn error of immunity
0.37
gout
0.17
Sepsis
0.14
Back pain
0.14
COVID-19
0.14
acute respiratory distress syndrome
0.12
rheumatoid arthritis
0.12
amyotrophic lateral sclerosis
0.12
neoplasm
0.12

Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.

Protein function (UniProt)

Monocyte differentiation antigen CD14

Coreceptor for bacterial lipopolysaccharide (PubMed:1698311, PubMed:23264655). In concert with LBP, binds to monomeric lipopolysaccharide and delivers it to the LY96/TLR4 complex, thereby mediating the innate immune response to bacterial lipopolysaccharide (LPS) (PubMed:20133493, PubMed:22265692, PubMed:23264655). Acts via MyD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (PubMed:8612135). Acts as a coreceptor for TLR2:TLR6 heterodimer in response to diacylated lipopeptides and for TLR2:TLR1 heterodimer in response to triacylated lipopeptides, these clusters trigger signaling from the cell surface and subsequently are targeted to the Golgi in a lipid-raft dependent pathway (PubMed:16880211). Binds electronegative LDL (LDL(-)) and mediates the cytokine release induced by LDL(-) (PubMed:23880187)